Evidence map›Paper›PMID 17634114›Full record

ArticleBMC biotechnology2007

Lentiviral vectors encoding tetracycline-dependent repressors and transactivators for reversible knockdown of gene expression: a comparative study.

Krzysztof Pluta, William Diehl, Xian-Yang Zhang, Robert Kutner, Agnieszka Bialkowska, Jakob Reiser

Open access · goldAbstract readComparative Study
In one paragraph

Article in BMC biotechnology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 37 citations in OpenAlex.

  1. MicroRNAs Regulating Autophagy in Neurodegeneration.Advances in experimental medicine and biology · 2021
    Article
  2. Article
  3. Article
  4. Article
  5. Lentiviral delivery of short hairpin RNAs.Advanced drug delivery reviews · 2009
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Krzysztof PlutaGene Therapy Program, Department of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA. plutak@gmail.com <plutak@gmail.com>
William Diehl
Xian-Yang Zhang
Robert Kutner
Agnieszka Bialkowska
Jakob Reiser
Louisiana State University Health Sciences Center New Orleans · US

Funding

Delivery of Therapeutic Enzymes and Genes to the CNSR01NS044832 · NINDS · LSU HEALTH SCIENCES CENTER · PI ZHANG, XIAN-YANG · 2003 to 2006
$913k
NINDS NIH HHS R01 NS044832
6 · The paper itself

Abstract

backgroundRNA interference (RNAi)-mediated by the expression of short hairpin RNAs (shRNAs) has emerged as a powerful experimental tool for reverse genetic studies in mammalian cells. A number of recent reports have described approaches allowing regulated production of shRNAs based on modified RNA polymerase II (Pol II) or RNA polymerase III (Pol III) promoters, controlled by drug-responsive transactivators or repressors such as tetracycline (Tet)-dependent transactivators and repressors. However, the usefulness of these approaches is often times limited, caused by inefficient delivery and/or expression of shRNA-encoding sequences in target cells and/or poor design of shRNAs sequences. With a view toward optimizing Tet-regulated shRNA expression in mammalian cells, we compared the capacity of a variety of hybrid Pol III promoters to express short shRNAs in target cells following lentivirus-mediated delivery of shRNA-encoding cassettes.

resultsRNAi-mediated knockdown of gene expression in target cells, controlled by a modified Tet-repressor (TetR) in the presence of doxycycline (Dox) was robust. Expression of shRNAs from engineered human U6 (hU6) promoters containing a single tetracycline operator (TO) sequence between the proximal sequence element (PSE) and the TATA box, or an improved second-generation Tet-responsive promoter element (TRE) placed upstream of the promoter was tight and reversible as judged using quantitative protein measurements. We also established and tested a novel hU6 promoter system in which the distal sequence element (DSE) of the hU6 promoter was replaced with a second-generation TRE. In this system, positive regulation of shRNA production is mediated by novel Tet-dependent transactivators bearing transactivation domains derived from the human Sp1 transcription factor.

conclusionOur modified lentiviral vector system resulted in tight and reversible knockdown of target gene expression in unsorted cell populations. Tightly regulated target gene knockdown was observed with vectors containing either a single TO sequence or a second-generation TRE using carefully controlled transduction conditions. We expect these vectors to ultimately find applications for tight and reversible RNAi in mammalian cells in vivo.

Indexed as

Gene SilencingTetracyclineGene ExpressionGene TargetingGenetic VectorsLentivirusRepressor ProteinsTrans-ActivatorsTransfectionRepressor ProteinsTetracyclineTrans-Activators

Identifiers

PMID17634114
PMCPMC1959519
OpenAlexW1987346834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.